Lexicon Pharmaceuticals, Inc.
LXRX
$0.3918
$0.02416.55%
| 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | |
|---|---|---|---|---|---|
| Revenue | 5.23M | 3.64M | 2.31M | 1.21M | 531.00K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 5.23M | 3.64M | 2.31M | 1.21M | 531.00K |
| Cost of Revenue | 72.90M | 64.61M | 61.35M | 58.97M | 58.12M |
| Gross Profit | -67.67M | -60.97M | -59.04M | -57.77M | -57.59M |
| SG&A Expenses | 143.45M | 136.09M | 126.90M | 113.98M | 97.71M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 216.35M | 200.70M | 188.25M | 172.96M | 155.82M |
| Operating Income | -211.12M | -197.06M | -185.94M | -171.75M | -155.29M |
| Income Before Tax | -216.39M | -202.11M | -193.58M | -177.12M | -157.86M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -216.39 | -202.11 | -193.58 | -177.12 | -157.86 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -216.39M | -202.11M | -193.58M | -177.12M | -157.86M |
| EBIT | -211.12M | -197.06M | -185.94M | -171.75M | -155.29M |
| EBITDA | -210.56M | -196.47M | -185.36M | -171.20M | -154.78M |
| EPS Basic | -0.75 | -0.78 | -0.83 | -0.80 | -0.76 |
| Normalized Basic EPS | -0.47 | -0.49 | -0.52 | -0.50 | -0.47 |
| EPS Diluted | -0.75 | -0.78 | -0.83 | -0.80 | -0.76 |
| Normalized Diluted EPS | -0.47 | -0.49 | -0.52 | -0.50 | -0.47 |
| Average Basic Shares Outstanding | 1.16B | 1.05B | 940.02M | 883.65M | 827.45M |
| Average Diluted Shares Outstanding | 1.16B | 1.05B | 940.02M | 883.65M | 827.45M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
